Today’s Solutions: November 14, 2024

A drug study involving people with rectal cancer has remarkably eradicated the tumor in all 18 patients. Though small, the trial astounded practitioners in the field, touting the results as an unprecedented achievement in cancer treatment, reports The New York Times.

Cancer disappeared in all patients

Led by Dr. Luis A. Diaz Jr from Memorial Sloan Kettering Cancer Center, the study was sponsored by GlaxoSmithKline, the drug company behind the medicine in the trial, dostarlimab. Dr. Diaz said the study was the first time a cancer treatment successfully eliminated cancer in all patients. “I believe this is the first time this has happened in the history of cancer,” Dr. Diaz said.

Rectal cancer patients often have to go through debilitating treatments, including chemotherapy, radiation, and surgeries with often life-altering side effects. The patients in the recent study entered the trial thinking that’s what awaits them as well since no one expected their cancer to go away.

But little did they know that no further treatment would be needed. “There were a lot of happy tears,” said Dr. Andrea Cercek, an oncologist at Memorial Sloan Kettering Cancer Center and study co-author.

No clinically significant adverse effects

What’s also important to note is that none of the patients experienced clinically significant complications. Typically, one in five patients has some kind of adverse effects from drugs like dostarlimab, also known as checkpoint inhibitors. The patients received the medication every three weeks for over half a year. It works by exposing cancer cells, allowing the immune system to identify and obliterate them.

It was another rectal cancer study from 2017 that inspired Dr. Diaz to conduct the new trial. That one involved administering pembrolizumab, also a checkpoint inhibitor, to 86 patients with metastatic cancer. About one-third to one-half of those patients lived longer because their tumors either shrank or stabilized. Meanwhile, cancer completely disappeared in only 10 percent of the patients.

As such, Dr. Diaz hypothesized that similar treatment would be more successful if administered to patients earlier in the course of the disease, before metastasis. After initially struggling to find a sponsor for the study, Dr. Cercek and Dr. Diaz eventually managed to put together the small trial, which would turn out to be life-changing for the 18 participants.

Source study: New England Journal of MedicinePD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

This story was part of our Best of 2022 series highlighting our top solutions from the year. Today we’re featuring a few amazing articles you may have missed!

Solutions News Source Print this article
More of Today's Solutions

Two Black women to serve together in the United States Senate in a historic f...

BY THE OPTIMIST DAILY EDITORIAL TEAM For the first time in American history, two Black women will serve together in the Senate. Angela Alsobrooks, ...

Read More

Resilient community-building: staying safe in times of uncertainty

BY THE OPTIMIST DAILY TEAM Recent global and domestic developments have left many feminists and allies feeling uneasy, uncertain about their place in society, ...

Read More

3 lifestyle hacks to help you become a little happier

There is no one path to finding happiness, but there are some lifestyle changes you can make to become more receptive to happiness. Without ...

Read More

For the first time ever, Greece meets energy demands with 100% renewables

The other week, Greece celebrated an exciting milestone! All of the country’s electricity needs were met by renewable energy for the first time, as ...

Read More